



■
**Reference
Section I**
Patient survival

table i.1 · 497**incident patient counts: ESRD patients***by age, gender, race, ethnicity, & primary diagnosis***table i.2 · 498****one-year survival probabilities: incident ESRD patients***from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis***table i.3 · 499****two-year survival probabilities: incident ESRD patients***from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis***table i.4 · 500****five-year survival probabilities: incident ESRD patients***from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis***table i.5 · 501****ten-year survival probabilities: incident ESRD patients***from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis***table i.6 · 502****incident patient counts: ESRD patients age 65 & over***patients age 65 & over on day 1, by age, gender, race, ethnicity, & primary diagnosis***table i.7 · 503****one-year survival probabilities: incident ESRD patients age 65 & over***from day 1 to one year, by age, gender, race, ethnicity, & primary diagnosis***table i.8 · 504****two-year survival probabilities: incident ESRD patients age 65 & over***from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis***table i.9 · 505****five-year survival probabilities: incident ESRD patients age 65 & over***from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis***table i.10 · 506****ten-year survival probabilities: incident ESRD patients age 65 & over***from day 1 to ten years, by age, gender, race, ethnicity, & primary diagnosis***table i.11 · 507****incident patient counts: dialysis patients***dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis***table i.12 · 508****one-year survival probabilities: incident dialysis patients***censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis***table i.13 · 509****two-year survival probabilities: incident dialysis patients***censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis***table i.14 · 510****five-year survival probabilities: incident dialysis patients***censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis***table i.15 · 511****ten-year survival probabilities: incident dialysis patients***censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

Table I.1

Incident Patient Counts: ESRD Patients

by age, gender, race, ethnicity, & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	40	63	93	100	100	119	112	120	125	134	118	158	143	160	130	164	182	184	170	176	207
5-9	88	95	102	89	101	98	116	97	95	120	142	135	120	140	160	156	151	135	140	173	166
10-14	169	183	209	205	216	198	190	205	214	208	209	239	238	246	260	286	281	283	277	315	328
15-19	409	461	447	426	411	403	425	454	466	510	484	476	487	515	536	579	595	541	545	623	595
20-29	1,444	1,629	1,852	1,772	1,889	1,962	2,014	2,022	2,153	2,343	2,385	2,469	2,542	2,565	2,683	2,688	2,713	2,633	2,760	2,686	2,715
30-39	2,087	2,418	2,651	2,747	2,914	3,119	3,417	3,465	3,883	4,228	4,421	4,704	5,010	4,997	5,571	5,799	5,745	5,719	5,763	5,931	5,793
40-49	2,286	2,620	2,757	3,081	3,178	3,480	3,736	4,151	4,546	5,228	5,658	6,452	6,932	7,143	8,009	8,961	9,447	9,421	10,236	10,506	10,812
50-59	3,502	4,132	4,451	4,572	4,805	5,109	5,356	5,749	6,469	7,010	7,547	8,179	9,106	9,329	11,018	11,749	12,232	13,301	14,448	15,626	16,215
60-64	1,953	2,249	2,566	2,999	3,288	3,596	3,751	4,239	4,593	5,057	5,457	6,088	6,390	6,550	7,291	7,794	8,032	8,405	8,880	9,194	9,468
65-69	1,938	1,975	2,274	3,061	3,098	3,521	4,037	4,597	5,114	5,934	6,584	7,353	7,909	8,216	8,957	8,919	9,628	9,954	10,211	10,370	10,484
70-79	2,148	2,315	2,899	4,165	4,282	4,976	5,732	6,542	7,210	8,567	9,559	11,286	12,567	13,166	14,905	15,217	17,102	18,200	19,270	20,527	21,014
80+	359	377	540	848	911	1,135	1,383	1,618	1,953	2,408	2,798	3,278	3,830	4,142	4,722	5,127	6,070	6,883	7,597	8,530	9,260
Male	9,165	10,239	11,476	13,203	13,906	15,066	16,542	17,981	19,845	22,611	24,467	27,227	29,258	30,553	33,994	35,587	38,501	40,262	42,686	45,249	46,635
Female	7,258	8,278	9,365	10,862	11,287	12,650	13,727	15,278	16,976	19,136	20,895	23,590	26,016	26,616	30,248	31,852	33,677	35,397	37,611	39,408	40,422
White	10,128	11,758	13,981	15,718	16,533	18,179	19,865	21,575	23,760	26,981	29,422	32,884	35,475	36,011	39,948	40,964	43,662	47,308	49,848	53,497	55,340
Black	5,624	6,013	6,169	7,394	7,517	8,264	8,895	9,966	11,220	13,102	13,927	15,668	17,133	18,190	20,445	21,503	22,877	23,139	24,627	25,319	25,378
Other race	671	746	691	953	1,143	1,273	1,509	1,718	1,841	1,664	2,013	2,265	2,666	2,968	3,849	4,972	5,639	5,212	5,822	5,841	6,339
†Hispanic																	8,627	8,652	9,540	10,119	10,909
†Non-Hispanic																	63,551	67,007	70,757	74,538	76,148
Diabetes	2,191	3,493	4,820	5,626	6,794	7,835	9,039	10,136	11,413	13,897	15,624	18,217	20,248	20,108	24,042	27,342	31,046	33,238	35,439	37,275	38,945
Hypertension	2,479	3,842	5,175	5,623	6,288	7,197	7,830	8,888	10,066	11,893	12,834	14,542	16,238	15,538	18,249	16,886	18,354	19,516	20,649	21,875	22,364
Glomerulonephritis	2,124	3,046	3,807	3,989	4,213	4,422	4,505	4,803	5,112	5,465	5,761	6,092	6,360	6,252	6,977	7,458	7,954	7,891	8,038	8,014	7,833
Cystic kidney	622	849	1,010	1,048	1,083	1,138	1,229	1,258	1,254	1,261	1,426	1,510	1,589	1,541	1,708	1,856	1,840	1,929	2,107	2,124	2,135
Other urologic	258	378	397	471	468	599	603	607	666	735	775	1,058	1,100	973	1,049	1,248	1,492	1,403	1,448	1,561	1,497
Other cause	1,565	2,197	2,990	3,344	3,572	3,890	3,973	4,115	4,189	4,632	4,510	4,739	5,008	4,944	5,706	7,308	7,715	7,988	8,558	9,001	9,310
Unknown cause	1,291	1,488	1,277	1,271	1,309	1,315	1,551	1,799	1,780	1,647	1,740	2,091	2,300	2,070	2,241	2,354	2,697	2,809	3,080	3,114	3,446
Missing cause	5,893	3,224	1,365	2,693	1,466	1,320	1,539	1,653	2,341	2,217	2,692	2,568	2,431	5,743	4,270	2,987	1,080	885	978	1,693	1,527
All	16,423	18,517	20,841	24,065	25,193	27,716	30,269	33,259	36,821	41,747	45,362	50,817	55,274	57,169	64,242	67,439	72,178	75,659	80,297	84,657	87,057

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.2
One-year Survival Probabilities: Incident ESRD Patients

from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	92.5	92.1	90.3	90.0	86.0	90.8	94.6	92.5	82.4	86.6	89.8	87.3	90.9	90.6	91.5	91.5	92.3	90.8	88.8	88.6	85.8
5-9	95.5	96.8	95.1	97.8	95.0	94.9	98.3	99.0	100.0	98.3	97.9	98.5	97.5	97.1	99.4	96.8	96.0	96.3	100.0	96.5	96.9
10-14	97.0	97.8	98.6	98.0	97.2	98.0	98.9	98.5	96.3	95.7	97.6	97.9	95.8	95.9	99.6	97.6	97.2	97.2	97.8	98.1	97.5
15-19	96.6	95.9	96.2	94.8	96.6	96.0	96.0	96.0	97.4	98.4	97.7	96.6	96.7	97.1	96.6	96.7	97.1	98.5	96.5	97.9	98.2
20-29	92.0	93.4	93.8	93.5	93.6	92.5	94.3	92.6	93.3	93.3	93.7	93.5	94.6	94.2	94.0	93.2	94.5	95.5	95.3	95.6	94.0
30-39	89.3	89.2	89.1	90.2	89.0	89.3	89.8	89.2	90.4	90.1	91.0	90.4	90.9	90.6	90.7	89.2	90.4	91.3	91.5	91.3	91.6
40-49	87.8	87.5	86.7	87.7	87.9	87.8	87.7	88.2	89.0	88.7	89.6	88.7	89.1	89.8	89.2	89.5	89.6	90.3	89.2	89.9	90.1
50-59	83.2	83.6	84.2	81.8	82.1	82.1	82.7	83.4	83.8	83.5	84.6	84.8	85.6	85.6	86.1	85.9	85.5	86.1	85.8	86.3	86.0
60-64	78.4	77.8	78.1	77.6	76.1	76.4	77.3	76.7	76.8	78.3	79.0	79.7	80.2	81.6	81.5	80.4	81.7	82.0	80.3	81.5	81.2
65-69	72.8	73.6	73.4	72.0	72.7	71.1	73.1	73.1	73.3	74.0	75.6	75.2	75.6	77.3	76.5	77.2	77.8	76.7	76.2	76.5	77.2
70-79	66.9	68.1	68.3	65.4	66.3	66.7	66.4	65.5	66.0	67.3	68.5	68.3	68.4	70.1	70.1	70.3	70.7	69.6	69.7	69.4	69.4
80+	57.7	53.8	62.0	55.2	56.8	58.0	58.8	55.5	55.4	57.8	59.3	59.3	58.4	60.9	60.7	60.2	60.0	59.4	57.4	58.4	58.3
Male	81.1	82.0	81.6	79.1	79.1	78.7	78.6	78.2	78.1	78.7	79.6	79.1	79.1	80.4	80.0	79.9	80.1	79.8	79.2	79.5	79.2
Female	81.9	81.9	81.9	79.6	79.8	79.1	79.8	78.5	79.3	79.1	79.7	79.2	79.5	79.8	79.9	79.8	79.6	79.0	78.2	78.2	78.2
White	80.6	80.8	80.3	77.5	77.1	76.9	77.0	75.8	76.2	76.5	77.2	76.5	76.6	77.6	77.4	77.5	77.4	76.6	76.2	76.6	76.4
Black	82.9	84.1	84.7	82.6	83.9	82.5	83.1	83.3	83.2	82.9	83.9	83.5	83.8	83.8	83.8	83.3	83.5	83.8	82.6	82.6	82.1
Other race	81.7	82.6	86.3	83.5	83.2	83.0	84.2	81.3	82.8	85.9	86.6	87.5	86.2	88.0	85.9	84.8	83.7	84.9	84.0	84.1	85.4
†Hispanic																	83.8	83.5	83.6	83.4	84.6
†Non-Hispanic																	79.3	78.9	78.1	78.3	77.9
Diabetes	74.9	74.1	73.9	74.2	74.5	73.9	75.3	75.0	76.0	76.8	76.9	77.3	77.6	79.5	78.9	78.7	79.0	78.3	77.6	78.2	78.3
Hypertension	82.9	81.9	80.6	78.3	77.8	78.5	77.5	75.8	75.6	76.2	77.5	76.4	76.7	77.4	77.3	78.5	78.3	77.5	76.9	76.8	76.7
Glomerulonephritis	91.5	89.9	89.5	88.2	88.0	88.1	86.9	87.0	86.9	86.8	87.4	86.2	87.8	88.8	87.3	88.3	88.9	88.7	88.9	88.2	88.5
Other cause	80.3	82.4	83.8	79.1	80.2	79.0	80.6	80.0	80.4	80.6	82.0	81.7	81.1	80.1	81.5	79.4	78.7	79.5	78.7	78.7	78.0
All	81.4	82.0	81.8	79.3	79.4	78.9	79.2	78.4	78.6	78.9	79.7	79.1	79.3	80.1	80.0	79.9	79.8	79.4	78.7	78.9	78.7
ADJUSTED																					
0-19	92.8	92.4	92.1	90.9	90.9	91.4	93.8	93.1	91.2	92.8	93.8	91.8	92.0	92.3	94.6	93.0	93.1	93.8	92.8	93.5	92.3
20-44	87.9	88.5	88.9	89.3	89.1	88.9	89.5	89.0	90.0	89.6	90.6	90.0	90.4	90.2	90.3	89.6	90.6	91.3	90.9	91.1	91.1
45-64	79.4	80.0	80.9	79.9	79.8	80.1	81.1	81.2	81.6	82.7	83.5	83.9	84.7	85.2	85.4	85.2	85.6	86.3	85.5	86.2	86.0
65-74	69.2	70.3	71.9	69.0	70.0	69.1	70.4	70.5	71.0	72.0	73.6	73.3	73.8	75.4	74.8	75.6	76.1	75.4	75.2	75.4	75.7
75+	59.8	61.9	61.6	58.6	60.8	62.0	62.1	59.3	60.0	62.3	63.3	63.4	62.8	64.1	65.0	64.5	64.9	63.9	63.2	63.5	63.5
Male	73.0	74.1	74.5	73.0	73.3	73.5	74.1	74.1	74.3	75.7	77.1	77.0	77.4	78.8	78.7	78.6	79.5	79.7	79.3	79.9	79.7
Female	74.6	75.0	76.5	75.2	75.8	75.7	77.1	76.3	77.4	77.9	79.0	78.9	79.4	79.7	80.1	80.1	80.3	80.1	79.5	79.6	79.9
White	71.4	72.1	72.9	71.4	71.5	72.0	73.0	72.4	73.4	74.6	75.8	75.7	76.3	77.4	77.9	78.1	78.7	78.4	78.1	78.7	78.7
Black	78.2	78.8	79.7	78.5	80.0	78.7	79.8	80.3	80.0	80.0	81.5	81.3	81.7	82.0	81.7	81.1	81.7	82.3	81.0	81.0	80.8
Other race	72.1	74.0	78.6	76.9	76.4	78.0	80.0	77.2	79.5	83.4	84.5	85.7	84.6	86.8	84.4	83.8	83.1	84.5	83.6	84.1	85.2
Diabetes	68.2	67.6	68.2	69.1	69.8	69.5	71.7	71.8	73.5	74.7	75.3	76.1	76.6	78.6	78.4	78.2	78.8	78.5	77.9	78.7	78.9
Hypertension	80.1	79.8	79.4	78.1	77.7	79.1	78.8	77.7	77.8	78.7	80.2	79.6	79.7	80.5	80.5	81.4	81.5	81.0	80.6	80.7	80.7
Glomerulonephritis	84.9	83.5	82.9	82.0	82.2	83.1	81.7	82.1	82.0	82.8	83.4	82.5	84.2	85.3	84.2	84.9	86.1	85.7	85.9	85.5	85.7
Other cause	76.1	76.8	78.8	76.4	76.8	75.4	77.4	77.0	77.1	77.4	79.0	78.6	78.6	78.8	78.7	76.7	76.4	77.5	76.6	76.7	76.0
All	73.8	74.6	75.5	74.1	74.5	74.6	75.6	75.2	75.8	76.8	78.0	78.0	78.4	79.3	79.4	79.4	79.9	79.9	79.4	79.8	79.8

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.3

Two-year Survival Probabilities: Incident ESRD Patients

from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	85.0	90.5	86.0	83.0	83.0	84.9	91.1	89.2	78.4	82.8	85.6	85.4	90.9	88.1	86.9	87.2	88.5	87.0	85.3	86.9
5-9	93.2	93.7	93.1	94.4	93.1	93.9	94.0	96.9	96.8	97.5	95.1	98.5	97.5	93.6	96.9	95.5	95.4	95.6	97.9	95.4
10-14	94.7	95.1	96.7	97.1	95.4	96.0	95.8	98.0	95.3	94.2	95.2	97.1	94.5	94.3	98.8	95.5	95.7	95.4	96.0	97.5
15-19	95.1	93.1	93.5	92.5	93.7	94.3	93.2	94.7	95.1	96.7	95.7	94.3	95.1	95.0	95.1	95.0	93.8	95.6	94.7	95.4
20-29	86.4	87.8	88.9	87.5	88.2	86.7	88.9	86.1	88.5	89.2	88.8	88.6	90.0	90.3	90.1	88.8	90.5	91.2	91.8	91.7
30-39	80.5	81.5	80.8	82.6	80.3	80.4	81.3	81.2	83.2	82.8	83.4	82.8	83.4	84.3	83.3	82.7	83.4	84.8	84.8	85.3
40-49	76.8	76.9	76.8	76.5	77.5	77.9	77.2	78.1	79.0	78.5	80.6	78.5	80.1	80.2	80.2	80.7	80.5	81.7	81.1	81.2
50-59	70.5	70.6	71.0	68.5	67.8	67.9	68.6	68.8	69.7	70.9	71.2	71.8	72.6	73.3	74.4	73.6	73.7	74.4	73.5	74.7
60-64	63.7	61.7	61.6	62.0	59.4	58.8	60.9	59.9	60.6	62.1	62.6	63.8	64.3	66.0	66.5	65.1	67.0	67.2	65.7	67.5
65-69	54.6	56.2	55.1	52.3	55.3	53.1	54.0	55.4	56.1	56.2	56.8	57.1	58.3	60.1	59.1	60.0	60.9	59.4	59.5	59.9
70-79	46.6	48.8	48.9	44.2	46.5	46.9	46.5	45.6	46.4	47.8	48.0	48.3	49.1	50.2	50.4	50.9	51.6	49.7	50.8	50.9
80+	30.4	33.7	37.4	30.4	36.7	35.6	35.1	33.3	33.1	37.4	36.7	36.3	36.6	37.5	38.4	38.3	38.1	37.1	37.1	37.4
Male	67.7	69.4	68.6	64.8	65.2	63.7	64.3	63.4	64.0	64.7	64.8	64.4	64.7	66.1	65.9	66.3	66.0	65.5	65.4	65.8
Female	69.3	69.3	68.8	65.1	65.8	65.4	64.8	64.2	64.9	64.9	64.9	64.2	65.0	65.0	65.4	65.1	65.2	64.1	63.8	64.0
White	67.2	68.0	66.7	62.7	62.5	62.0	61.6	60.8	60.9	61.4	61.3	60.6	61.0	61.6	61.6	61.8	61.7	60.6	60.9	61.5
Black	70.3	71.7	72.5	68.9	71.0	69.3	70.1	69.2	71.0	70.6	70.9	70.2	71.1	71.7	71.9	71.6	71.7	70.5	70.4	70.4
Other race	70.6	70.1	75.4	70.8	71.4	68.5	70.6	68.8	70.0	74.5	74.6	77.7	75.7	77.0	74.4	72.5	72.0	73.1	72.4	73.2
†Hispanic																	71.1	70.6	71.1	71.7
†Non-Hispanic																	64.9	64.1	63.8	64.0
Diabetes	57.4	56.3	55.6	57.1	55.4	55.6	56.6	56.6	58.0	59.5	58.6	59.5	60.3	62.2	61.7	61.8	62.3	61.4	61.2	62.2
Hypertension	69.8	68.3	67.0	63.1	64.2	63.2	62.1	60.1	60.8	61.4	61.5	60.6	61.7	62.3	62.5	64.0	63.8	62.3	62.2	62.1
Glomerulonephritis	83.3	81.1	80.9	78.7	79.2	77.7	76.7	76.8	77.8	76.8	77.6	76.0	78.1	79.7	77.9	79.2	79.7	79.4	80.5	79.4
Other cause	67.2	71.0	72.2	64.9	67.8	67.0	68.6	68.1	68.5	69.5	70.8	70.4	69.8	67.8	70.2	67.9	67.4	68.0	67.6	67.8
All	68.4	69.3	68.7	64.9	65.4	64.5	64.5	63.7	64.4	64.8	64.8	64.3	64.9	65.6	65.7	65.7	65.7	64.8	64.7	65.0
ADJUSTED																				
0-19	88.9	87.5	87.4	86.2	86.5	87.2	88.1	90.5	87.2	89.6	89.3	89.1	90.1	88.4	91.4	89.4	88.6	89.4	89.2	90.5
20-44	77.7	79.6	80.2	80.4	80.2	80.0	80.9	80.3	82.2	82.1	82.9	81.8	82.8	82.9	83.0	82.4	83.4	84.6	84.2	84.6
45-64	64.9	64.9	66.1	65.2	64.5	64.8	66.2	66.1	67.2	69.0	69.7	70.4	71.5	72.4	73.2	72.8	73.8	74.5	73.7	74.8
65-74	49.2	52.0	53.0	48.4	51.5	50.3	51.1	51.9	53.1	53.8	54.3	54.8	56.1	57.0	56.8	58.2	58.8	57.5	58.2	58.6
75+	37.4	41.0	39.5	35.5	40.1	40.7	40.0	38.0	38.5	41.9	41.7	41.8	41.9	43.0	43.9	43.4	44.4	42.8	43.5	43.9
Male	55.9	57.8	58.0	56.1	57.0	56.4	58.0	57.4	58.7	60.5	61.1	61.4	62.3	63.9	64.1	64.4	65.2	65.3	65.5	66.3
Female	58.8	59.4	60.8	58.8	60.2	60.7	60.9	61.2	62.1	63.3	63.8	64.0	65.1	65.0	65.9	65.7	66.6	66.0	65.9	66.3
White	54.2	55.7	56.1	54.2	54.9	55.4	55.9	56.1	57.1	59.0	59.4	59.7	60.8	61.5	62.5	62.9	63.8	63.3	63.8	64.7
Black	63.0	63.5	64.7	62.7	64.7	63.5	65.1	64.5	66.1	66.2	67.1	66.9	67.9	68.9	68.8	68.3	69.0	69.2	68.2	68.1
Other race	57.3	57.6	63.3	60.2	61.4	60.8	63.7	62.7	65.0	70.5	70.8	74.6	73.2	74.9	71.9	71.0	71.1	72.6	71.8	73.3
Diabetes	49.0	48.2	48.4	50.7	49.5	50.3	51.9	52.7	54.7	56.8	56.7	58.0	59.1	61.3	61.3	61.4	62.3	61.9	61.9	63.2
Hypertension	65.4	65.3	65.3	62.8	64.2	64.3	64.2	63.0	64.0	65.1	65.7	65.4	66.1	66.9	67.5	68.3	68.6	67.7	67.8	67.9
Glomerulonephritis	71.5	70.2	70.0	68.5	70.0	69.1	68.4	68.8	70.1	70.2	71.1	70.1	72.2	73.6	72.9	73.6	74.9	74.3	75.5	75.0
Other cause	61.3	63.0	64.7	60.8	62.7	61.9	63.9	63.7	63.8	65.1	66.3	65.8	66.2	65.8	66.0	64.2	64.2	65.1	64.7	64.9
All	57.3	58.6	59.4	57.4	58.5	58.5	59.4	59.2	60.3	61.9	62.4	62.7	63.7	64.5	65.0	65.0	65.9	65.7	65.7	66.3

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.4
Five-year Survival Probabilities: Incident ESRD Patients

from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996
0-4	77.5	77.8	81.7	79.0	76.0	81.5	82.1	81.7	76.0	79.9	82.2	82.9	86.0	83.8	83.8	82.3	82.8
5-9	88.6	89.5	86.3	89.9	89.1	88.8	90.5	94.8	93.7	95.0	91.5	96.3	94.2	90.7	94.4	93.6	90.7
10-14	87.6	85.8	91.4	91.7	90.7	91.9	91.6	95.1	92.1	89.4	90.9	92.5	88.2	89.4	94.6	93.0	92.9
15-19	89.7	87.6	88.1	88.5	86.9	85.4	88.0	87.9	88.0	90.0	90.5	88.9	90.6	89.9	89.6	90.3	88.7
20-29	78.0	76.8	78.8	76.1	76.4	76.2	78.7	76.4	79.2	78.8	79.6	80.0	80.3	81.2	82.0	79.8	81.9
30-39	64.9	66.0	64.8	65.5	64.9	64.5	66.4	63.8	68.2	68.5	69.0	67.8	67.9	70.1	68.8	68.8	69.2
40-49	54.7	55.7	55.7	53.9	56.9	56.5	57.3	58.0	58.6	57.5	59.0	58.1	59.7	60.2	59.6	60.9	59.7
50-59	41.8	43.0	41.9	40.6	40.1	39.3	41.3	42.5	41.9	42.5	42.5	44.6	43.8	45.8	46.4	46.1	46.0
60-64	31.6	31.7	29.9	30.1	28.0	28.0	29.5	28.5	30.7	30.9	31.8	31.8	32.7	33.5	34.4	33.8	35.1
65-69	23.1	24.8	24.1	20.9	22.6	22.7	22.4	23.4	23.3	23.6	23.7	23.1	24.8	25.3	26.2	26.0	26.8
70-79	16.0	16.0	17.2	13.8	15.6	15.6	14.9	15.5	15.6	16.2	15.9	16.3	16.1	16.9	17.1	17.7	18.3
80+	7.0	5.8	6.1	6.5	7.6	8.4	7.5	7.8	6.7	8.9	8.7	7.9	7.6	8.2	8.3	9.1	8.9
Male	44.0	44.7	44.2	39.8	40.2	39.0	39.7	38.9	39.2	39.6	39.1	38.6	38.2	39.6	39.3	40.4	39.5
Female	44.3	45.8	43.8	39.6	40.4	39.5	39.1	38.1	38.8	37.7	37.5	36.8	37.1	37.0	37.4	37.0	36.8
White	44.0	44.0	42.6	37.9	38.2	37.5	37.2	36.0	35.7	35.6	34.9	34.2	34.0	34.7	34.2	34.2	33.8
Black	44.2	47.4	46.3	42.3	43.9	42.1	43.0	42.5	44.7	43.5	43.9	43.3	43.6	43.8	45.0	46.0	44.8
Other race	46.3	46.8	52.5	50.1	46.9	44.9	47.3	47.7	47.4	51.9	50.3	51.4	48.4	49.6	48.1	46.1	45.9
†Hispanic																	44.4
†Non-Hispanic																	37.4
Diabetes	29.8	28.1	27.0	27.2	26.7	26.7	28.5	27.6	28.5	28.5	27.8	28.3	28.8	30.2	30.2	30.0	30.2
Hypertension	44.8	41.2	39.7	36.2	36.4	35.8	34.4	32.9	34.0	33.8	34.0	32.5	33.3	33.9	33.6	36.0	35.6
Glomerulonephritis	65.6	62.7	62.0	58.7	58.1	55.9	56.6	56.2	57.6	57.1	56.8	55.9	57.1	59.3	57.7	59.5	59.4
Other cause	42.5	47.9	49.1	41.4	45.5	45.2	46.1	46.7	46.5	48.2	48.7	49.4	47.8	45.2	48.7	47.3	46.9
All	44.2	45.2	44.0	39.7	40.3	39.2	39.4	38.5	39.0	38.7	38.4	37.8	37.7	38.4	38.4	38.8	38.2
ADJUSTED																	
0-19	79.4	76.4	78.4	79.1	76.9	76.6	79.6	81.4	79.1	81.1	82.0	81.9	82.2	81.0	84.0	83.4	81.3
20-44	60.8	62.3	62.9	62.1	63.7	63.2	65.4	63.6	66.2	66.8	67.5	66.4	67.0	68.1	68.0	67.6	68.2
45-64	34.7	36.1	36.6	35.9	35.6	35.7	37.9	38.3	39.4	40.4	40.8	42.4	43.0	44.3	45.1	45.6	46.4
65-74	18.1	19.9	20.7	17.3	19.3	19.6	19.1	20.3	20.8	21.4	21.6	21.3	22.8	22.8	23.9	24.3	25.2
75+	10.2	10.2	10.6	8.6	10.4	11.0	10.9	10.5	10.0	12.0	11.0	11.6	10.7	11.4	11.7	12.5	13.0
Male	30.5	31.0	31.6	29.7	30.7	30.8	32.2	32.2	32.9	34.7	34.6	35.0	35.2	36.7	37.0	37.9	38.5
Female	31.9	33.9	34.1	32.6	33.9	34.1	34.7	34.9	35.6	35.8	36.2	36.7	37.4	37.4	38.4	38.3	39.0
White	29.2	29.6	30.4	28.6	29.7	30.2	30.9	30.9	31.5	32.9	32.7	33.2	33.9	34.7	35.6	35.8	36.9
Black	34.6	36.6	35.9	34.2	35.8	35.0	36.7	36.7	38.1	37.7	38.8	39.0	39.2	40.1	40.6	41.4	41.1
Other race	30.3	32.0	35.8	36.0	33.8	35.1	37.6	39.7	40.6	45.7	44.0	46.3	44.5	46.0	44.3	44.1	44.6
Diabetes	23.1	21.7	21.8	22.4	22.4	23.0	24.9	24.9	26.2	26.8	26.8	27.9	28.7	30.2	30.8	30.7	31.4
Hypertension	39.4	37.7	38.2	36.5	36.9	37.6	37.2	37.1	38.0	38.7	39.4	38.6	39.0	39.8	39.9	41.5	41.8
Glomerulonephritis	46.2	45.7	45.1	43.6	44.2	42.5	44.3	44.1	45.6	46.6	46.0	46.9	47.3	48.9	49.0	50.0	50.8
Other cause	35.4	37.8	38.9	35.7	38.7	38.5	39.7	40.5	40.1	42.0	42.0	42.7	42.4	41.9	42.9	42.0	42.2
All	31.2	32.3	32.8	31.1	32.2	32.4	33.4	33.5	34.2	35.2	35.4	35.8	36.3	37.1	37.7	38.1	38.8

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.5

Ten-year Survival Probabilities: Incident ESRD Patients

from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	75.0	71.4	77.4	76.0	71.0	73.9	79.5	80.8	68.0	77.6	76.3	78.5
5-9	80.7	81.1	78.4	82.0	86.1	82.7	85.3	82.5	91.6	89.2	85.9	91.1
10-14	78.1	77.6	77.5	83.9	82.4	83.3	85.3	87.8	84.1	81.3	82.3	86.6
15-19	79.5	79.8	79.6	80.3	78.3	76.2	78.8	78.4	79.2	83.1	83.7	80.4
20-29	64.3	62.6	65.9	63.7	63.9	64.8	65.3	64.4	67.9	65.8	67.9	66.4
30-39	47.2	47.5	48.2	49.2	48.9	47.3	49.6	47.9	50.1	50.7	52.5	50.9
40-49	32.2	32.8	33.7	33.9	35.8	35.8	36.4	36.0	36.5	35.2	36.4	36.3
50-59	16.0	18.1	18.1	16.8	17.3	17.8	18.4	19.6	18.3	18.8	19.3	20.3
60-64	8.2	8.7	6.9	8.9	8.5	9.3	9.0	8.5	9.3	9.0	9.6	9.9
65-69	4.6	5.2	4.0	4.8	5.4	6.2	5.1	4.8	5.0	4.9	5.5	5.1
70-79	2.5	2.2	2.9	2.3	2.9	2.8	2.3	2.6	2.3	2.2	2.1	2.0
80+	1.4	0.5	1.5	0.2	1.3	0.9	0.6	0.9	0.4	0.6	0.4	0.9
Male	24.8	25.6	26.0	23.4	23.7	23.1	23.3	22.2	21.9	21.7	22.0	21.0
Female	24.9	25.8	24.3	21.9	22.5	21.9	20.9	20.1	20.4	19.3	18.9	18.6
White	26.1	26.3	25.6	22.9	23.1	22.5	22.0	21.0	20.2	19.7	19.8	18.9
Black	22.0	23.9	23.3	20.9	22.0	21.6	21.2	20.3	22.2	21.2	20.8	20.5
Other race	28.9	30.3	35.5	33.7	31.4	29.4	30.7	29.0	29.0	30.2	30.8	29.8
Diabetes	11.9	12.0	11.7	11.3	11.8	12.1	12.2	11.8	11.4	11.2	10.4	10.0
Hypertension	21.9	19.6	18.5	17.1	17.4	16.5	16.3	14.4	15.1	14.8	14.9	14.2
Glomerulonephritis	46.4	42.4	42.6	40.4	40.5	39.5	40.0	38.7	39.5	38.7	39.0	37.2
Other cause	23.8	28.2	30.2	25.5	28.3	28.6	28.5	28.9	29.2	30.2	31.9	33.1
All	24.8	25.7	25.3	22.7	23.2	22.5	22.2	21.2	21.2	20.6	20.6	19.9
ADJUSTED												
0-19	65.1	64.7	64.1	67.3	65.7	63.8	68.5	68.8	67.3	71.1	71.1	71.2
20-44	42.4	42.8	45.0	45.1	46.3	46.5	47.7	46.3	48.1	48.6	49.6	48.5
45-64	12.1	13.7	14.2	14.3	15.0	15.6	16.5	17.0	16.9	17.5	17.9	19.0
65-74	3.1	3.5	3.4	3.5	4.1	4.7	3.9	3.9	3.9	4.1	4.4	4.1
75+	1.2	1.3	1.8	0.8	1.8	1.5	1.2	1.5	1.2	1.1	0.9	1.2
Male	14.3	14.7	15.7	15.2	16.0	16.5	16.9	16.7	16.7	17.3	17.7	17.6
Female	15.4	16.6	16.6	16.4	17.5	17.7	17.3	17.6	17.8	17.7	18.0	18.4
White	14.5	14.9	15.5	15.3	16.2	16.5	16.6	16.8	16.5	17.1	17.4	17.6
Black	14.6	15.5	15.2	14.7	15.7	16.1	16.1	15.9	16.8	16.3	16.7	16.9
Other race	15.3	17.0	20.3	20.0	19.6	20.1	20.9	21.4	22.4	23.7	23.9	24.1
Diabetes	8.8	9.1	9.3	9.2	9.8	10.4	10.6	10.7	10.6	10.6	10.5	10.5
Hypertension	18.3	17.6	18.1	18.2	18.3	18.5	18.4	18.0	18.3	18.5	18.8	18.5
Glomerulonephritis	25.0	24.4	24.5	24.4	25.8	25.6	26.6	25.8	26.3	26.4	26.4	26.6
Other cause	18.0	19.5	20.6	19.7	21.5	21.9	21.6	22.4	22.4	23.4	24.5	25.5
All	14.8	15.5	16.1	15.8	16.6	17.0	17.1	17.1	17.2	17.5	17.8	18.0

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

Table I.6

Incident Patient Counts: ESRD Patients Age 65 & Over

patients age 65 & over on day 1, by age, gender, race, ethnicity, & primary diagnosis

	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	4,318	5,883	7,359	9,452	11,991	15,115	17,399	19,300	21,206	22,294	22,951
70-74	3,236	4,996	6,349	8,088	10,166	13,395	16,560	19,160	21,992	23,645	24,629
75-79	1,863	3,029	4,252	5,776	7,692	9,938	12,243	14,549	17,817	21,286	22,808
80-84	679	1,216	1,824	2,644	3,734	5,135	6,632	8,284	10,684	12,909	14,815
85+	203	435	647	936	1,416	2,071	2,747	3,458	4,844	6,693	7,995
Male	5,656	8,336	10,800	14,033	18,183	23,543	28,348	32,515	39,339	44,708	47,988
Female	4,643	7,223	9,631	12,863	16,816	22,111	27,233	32,236	37,204	42,119	45,210
White	6,930	11,226	14,684	19,302	25,293	32,941	39,630	45,996	54,393	62,555	67,775
Black	2,986	3,909	5,026	6,513	8,476	11,118	13,681	15,246	17,608	19,283	20,225
Other race	383	424	721	1,081	1,230	1,595	2,270	3,509	4,542	4,989	5,198
†Hispanic									6,984	8,160	9,067
†Non-Hispanic									69,559	78,667	84,131
Diabetes	1,235	2,633	4,231	6,467	9,553	14,133	17,841	23,622	31,230	36,294	40,087
Hypertension	2,590	5,236	7,289	10,110	13,858	18,270	21,256	23,590	26,000	29,563	31,568
Glomerulonephritis	1,030	1,835	2,400	2,877	3,458	4,141	4,283	5,140	5,709	5,714	5,220
Cystic kidney	270	423	466	574	603	739	762	966	1,011	1,058	1,082
Other urologic	342	442	636	780	921	1,125	1,159	1,291	1,602	1,683	1,677
Other cause	986	1,963	2,616	3,151	3,525	3,658	3,979	5,299	6,960	7,927	8,791
Unknown cause	1,193	1,250	1,373	1,878	2,057	2,326	2,606	2,753	3,430	3,931	4,338
Missing cause	2,653	1,777	1,420	1,059	1,024	1,262	3,695	2,090	601	657	435
All	10,299	15,559	20,431	26,896	34,999	45,654	55,581	64,751	76,543	86,827	93,198

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule.
 The age of the incident patient is determined as of the date of ESRD initiation.
 Patients of unknown age or gender, or of age >110 are excluded.
 †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.
 Includes patients from U.S. & territories only.

Table I.7

One-year Survival Probabilities: Incident ESRD Patients Age 65 & Over

from day 1 to one year, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99	2000-01
65-69	70.9	70.9	69.9	72.0	73.1	74.0	75.4	75.7	75.4	75.0	75.1
70-74	66.4	67.2	64.9	66.3	66.7	68.3	70.2	70.3	69.9	69.6	69.4
75-79	61.0	60.3	61.8	60.8	61.3	63.8	63.6	64.6	64.2	63.2	63.6
80-84	53.5	56.8	55.5	56.6	57.4	57.7	59.2	58.9	58.5	56.6	56.4
85+	46.3	50.8	47.3	48.8	46.9	51.1	51.1	51.8	48.8	47.5	48.6
Male	65.0	63.8	62.8	63.8	64.3	66.0	67.2	67.2	66.5	65.5	65.4
Female	67.3	68.5	66.7	67.5	67.7	68.6	69.0	69.2	67.9	66.1	65.8
White	64.8	63.7	62.4	62.6	63.1	64.4	65.2	65.6	64.9	63.9	63.7
Black	68.8	72.3	71.1	73.7	73.4	74.2	74.9	74.5	72.5	70.4	69.8
Other race	68.1	66.7	67.0	69.3	72.4	77.1	77.5	74.8	73.1	71.8	73.7
†Hispanic									71.2	70.7	71.3
†Non-Hispanic									66.8	65.3	64.9
Diabetes	64.3	61.3	63.4	65.1	66.8	68.3	70.0	69.8	69.3	67.8	67.8
Hypertension	68.3	65.9	65.1	64.8	64.5	65.6	65.7	66.8	66.2	65.0	64.6
Glomerulonephritis	74.2	73.7	73.5	72.5	72.5	72.8	74.9	74.0	74.4	73.5	74.2
Other cause	63.9	65.8	61.8	64.3	64.6	66.4	67.0	65.3	61.2	59.6	59.1
All	66.1	66.0	64.7	65.6	65.9	67.3	68.1	68.2	67.2	65.8	65.6
ADJUSTED											
65-69	68.6	69.3	68.6	71.1	72.6	73.7	75.2	75.7	75.6	75.3	75.6
70-74	64.6	66.0	63.8	65.5	66.2	68.1	70.0	70.3	70.0	70.0	69.9
75-79	59.5	59.0	60.8	59.9	60.6	63.4	63.3	64.3	64.2	63.5	64.0
80-84	52.3	56.0	54.6	55.9	56.8	57.1	58.7	58.5	58.4	56.7	56.6
85+	45.6	49.9	46.2	47.9	46.0	50.4	50.5	51.2	48.3	47.3	48.5
Male	60.5	60.4	60.0	61.4	62.4	64.6	66.2	66.7	66.5	66.3	66.6
Female	62.4	64.8	63.6	65.0	65.7	67.1	67.8	68.4	67.8	66.6	66.8
White	60.1	59.9	59.1	59.9	61.1	62.9	64.2	65.0	65.0	64.7	64.9
Black	65.2	69.6	68.5	71.5	71.4	72.6	73.5	73.3	71.8	70.0	69.7
Other race	63.4	63.8	64.2	67.1	70.9	75.6	76.4	73.9	72.9	72.1	74.2
Diabetes	58.1	56.2	58.7	60.6	62.9	64.8	66.9	67.0	66.9	66.0	66.6
Hypertension	65.7	64.2	63.8	64.1	64.3	65.9	66.3	67.7	67.7	67.2	67.3
Glomerulonephritis	71.6	71.8	72.0	71.4	71.8	72.6	74.8	74.4	75.0	74.6	75.2
Other cause	61.5	64.3	60.8	63.6	64.2	66.0	66.9	65.6	62.4	61.5	61.2
All	61.4	62.5	61.7	63.1	64.0	65.8	67.0	67.5	67.1	66.5	66.7

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables is adjusted for the remaining three.

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age, gender, & age >110 are excluded.

Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.8
Two-year Survival Probabilities: Incident ESRD Patients Age 65 & Over

from day 1 to two years, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97	1998-99
65-69	53.2	52.3	51.9	53.6	55.5	56.3	58.4	58.9	59.0	58.6
70-74	47.3	47.9	46.5	47.2	48.1	49.3	51.1	52.0	51.7	52.2
75-79	41.6	39.2	41.2	40.5	41.8	43.7	44.6	45.2	44.9	44.7
80-84	33.4	34.5	35.9	34.0	35.6	36.7	38.1	38.8	38.2	37.0
85+	27.1	29.0	27.2	26.8	28.3	28.5	29.4	30.1	29.1	28.3
Male	46.0	43.6	43.2	43.8	45.3	46.7	48.0	48.6	48.0	47.7
Female	49.2	49.4	48.6	48.4	49.1	49.4	50.7	50.8	49.7	48.0
White	46.1	43.8	43.3	42.7	43.9	44.5	45.6	46.4	45.9	45.4
Black	50.8	53.5	52.8	55.2	55.7	56.5	57.9	57.6	55.9	53.9
Other race	45.2	46.7	47.0	49.0	54.2	61.1	61.7	57.5	56.4	55.8
†Hispanic									53.0	53.3
†Non-Hispanic									48.4	47.3
Diabetes	40.9	39.0	41.9	42.4	45.0	46.7	49.5	49.6	49.3	48.8
Hypertension	49.3	46.3	46.7	45.2	46.3	46.6	47.3	48.8	48.4	47.1
Glomerulonephritis	55.9	55.9	54.4	53.7	54.6	55.6	57.7	56.9	57.2	57.1
Other cause	46.4	46.5	44.0	47.2	47.8	49.4	49.5	48.4	45.0	43.8
All	47.4	46.3	45.8	46.0	47.1	48.0	49.3	49.7	48.8	47.9
ADJUSTED										
65-69	49.8	49.8	50.0	52.1	54.7	55.9	58.1	58.9	59.5	59.2
70-74	44.7	46.0	44.9	46.1	47.3	48.9	50.7	51.9	51.9	52.7
75-79	39.5	37.4	39.8	39.3	40.8	43.1	44.1	44.9	45.0	45.0
80-84	31.9	33.3	34.7	33.0	34.9	35.9	37.4	38.4	38.0	37.1
85+	26.4	27.8	26.0	25.8	27.3	27.7	28.6	29.4	28.5	28.0
Male	40.3	39.3	39.7	40.9	42.9	45.0	46.6	47.8	48.1	48.7
Female	42.9	44.6	44.8	45.0	46.5	47.4	49.1	49.7	49.5	48.7
White	40.2	38.8	39.3	39.4	41.3	42.6	44.2	45.7	46.0	46.4
Black	46.1	49.7	49.5	52.1	53.0	54.3	56.0	55.9	55.0	53.3
Other race	39.1	42.7	43.7	46.2	52.2	58.9	60.1	56.2	56.2	56.3
Diabetes	34.0	33.5	36.6	37.1	40.3	42.4	45.5	46.0	46.4	46.6
Hypertension	46.1	44.3	45.3	44.3	46.0	47.0	48.1	50.0	50.4	49.9
Glomerulonephritis	52.4	53.5	52.6	52.3	53.9	55.4	57.6	57.5	58.1	58.7
Other cause	43.6	44.7	43.0	46.4	47.3	49.0	49.3	48.7	46.5	46.1
All	41.6	41.8	42.1	42.8	44.7	46.2	47.8	48.7	48.8	48.7

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.9

Five-year Survival Probabilities: Incident ESRD Patients Age 65 & Over

from day 1 to five years, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93	1994-95	1996-97
65-69	23.2	21.6	22.1	22.5	23.3	23.3	24.9	25.9	26.2
70-74	16.9	16.7	16.8	16.5	17.6	17.8	18.9	19.5	19.6
75-79	12.9	11.3	12.0	12.6	12.6	12.9	12.8	13.8	14.6
80-84	6.2	7.1	8.8	8.0	8.5	9.1	8.7	9.2	9.5
85+	4.4	3.7	3.9	4.7	5.3	5.2	5.5	5.8	5.5
Male	16.3	14.3	14.6	15.0	16.1	16.2	16.4	17.2	17.4
Female	19.8	18.8	18.8	18.2	17.9	17.8	18.8	19.0	18.6
White	16.7	15.1	14.9	14.4	14.7	14.4	15.0	15.4	15.6
Black	20.7	20.2	21.6	22.5	22.8	23.5	23.8	24.7	23.4
Other race	16.4	16.5	16.6	19.0	23.4	26.0	24.8	24.5	25.2
†Hispanic									20.6
†Non-Hispanic									17.7
Diabetes	11.6	10.5	12.1	12.4	13.0	13.7	15.2	16.0	16.1
Hypertension	19.0	17.1	16.4	16.1	16.5	16.4	16.5	17.6	18.1
Glomerulonephritis	23.2	23.1	21.3	21.6	23.0	23.1	24.4	24.8	25.3
Other cause	17.7	16.3	17.9	18.8	20.0	20.6	20.4	20.2	19.1
All	17.9	16.4	16.6	16.5	17.0	17.0	17.6	18.1	18.0
ADJUSTED									
65-69	19.8	19.2	20.1	20.9	22.3	22.7	24.4	25.8	26.7
70-74	14.8	15.0	15.5	15.5	16.7	17.3	18.4	19.4	19.8
75-79	11.1	10.1	10.9	11.6	11.9	12.4	12.4	13.5	14.7
80-84	5.7	6.5	8.1	7.4	8.2	8.6	8.4	9.0	9.4
85+	4.2	3.2	3.4	4.4	4.8	4.9	5.1	5.5	5.3
Male	12.2	11.3	12.2	12.9	14.3	14.8	15.2	16.5	17.4
Female	14.6	14.9	15.6	15.5	15.8	16.2	17.4	18.1	18.4
White	12.2	11.4	11.9	11.9	12.8	12.9	13.9	14.8	15.7
Black	16.5	16.7	18.7	19.8	20.2	21.4	21.7	23.0	22.5
Other race	12.4	13.6	14.3	16.7	21.5	23.9	23.1	23.1	24.9
Diabetes	8.0	7.8	9.3	9.5	10.2	11.1	12.5	13.5	14.0
Hypertension	16.4	15.5	15.3	15.5	16.3	16.6	17.1	18.5	19.6
Glomerulonephritis	20.3	21.3	20.1	20.5	22.6	23.1	24.5	25.2	26.3
Other cause	15.8	15.1	17.3	18.2	19.6	20.2	20.1	20.5	20.4
All	13.4	13.0	13.8	14.1	15.0	15.5	16.2	17.3	17.9

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age, gender, & age >110 are excluded. Includes U.S. & territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.10
Ten-year Survival Probabilities: Incident ESRD Patients Age 65 & Over
from day 1 to ten years, by age, gender, & race, ethnicity, & primary diagnosis

UNADJUSTED	1980-81	1982-83	1984-85	1986-87	1988-89	1990-91	1992-93
65-69	4.9	4.4	5.8	5.0	4.9	5.2	5.3
70-74	2.7	3.0	3.1	2.9	2.6	2.5	3.0
75-79	1.6	1.5	1.8	1.8	1.5	1.3	1.3
80-84	0.9	0.9	1.0	0.8	0.6	0.8	0.4
85+	0.5	.	0.6	0.1	0.4	0.3	0.5
Male	2.8	2.3	3.3	3.0	2.6	2.6	2.8
Female	3.8	3.8	3.9	3.2	3.1	3.1	3.0
White	3.0	2.6	3.3	2.7	2.3	2.3	2.5
Black	4.1	3.9	4.4	3.8	4.1	4.1	4.1
Other race	1.6	4.5	3.6	4.6	4.9	5.8	2.8
Diabetes	2.0	1.9	2.3	1.7	1.6	1.5	1.5
Hypertension	2.7	2.6	3.1	2.6	2.4	2.4	2.4
Glomerulonephritis	3.8	4.3	4.9	4.9	4.8	4.5	5.0
Other cause	3.7	3.4	4.4	4.1	4.4	5.0	5.2
All	3.3	3.0	3.6	3.1	2.8	2.8	2.9
ADJUSTED							
65-69	3.7	3.6	5.0	4.3	4.5	4.9	5.1
70-74	2.1	2.4	2.7	2.6	2.4	2.4	2.9
75-79	1.2	1.2	1.5	1.5	1.3	1.2	1.3
80-84	0.8	0.8	1.0	0.7	0.6	0.7	0.4
85+	0.5	.	0.6	0.1	0.3	0.3	0.5
Male	1.8	1.6	2.5	2.3	2.0	2.2	2.4
Female	2.2	2.5	2.9	2.4	2.5	2.6	2.6
White	1.7	1.6	2.2	1.9	1.7	1.8	2.1
Black	2.7	2.8	3.3	3.0	3.3	3.4	3.5
Other race	1.1	3.5	2.8	3.6	4.1	4.8	2.8
Diabetes	1.4	1.3	1.7	1.3	1.1	1.1	1.2
Hypertension	2.2	2.3	2.8	2.5	2.3	2.5	2.6
Glomerulonephritis	3.0	4.0	4.6	4.7	4.6	4.6	5.1
Other cause	3.1	3.0	4.2	4.0	4.3	4.8	5.1
All	2.0	2.0	2.7	2.4	2.3	2.4	2.5

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts and associated modalities are determined at the time of ESRD initiation with the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories. "." Zero values in this cell.

Table I.11

Incident Patient Counts: Dialysis Patients*dialysis patients alive on day 91, by age, gender, race, ethnicity, & primary diagnosis*

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	26	47	62	76	79	88	87	78	87	98	80	116	96	96	97	127	131	138	142	127	164
5-9	56	62	72	68	71	54	77	67	59	64	82	65	55	66	107	97	97	87	95	111	111
10-14	128	144	164	152	150	132	119	123	128	113	136	145	158	159	179	192	202	208	200	222	222
15-19	342	370	359	362	325	320	310	334	353	402	353	349	396	367	387	446	477	433	457	484	470
20-29	1,242	1,408	1,619	1,553	1,660	1,696	1,730	1,743	1,820	1,956	2,019	2,103	2,187	2,153	2,357	2,403	2,482	2,396	2,500	2,381	2,458
30-39	1,893	2,166	2,416	2,488	2,649	2,817	3,016	3,052	3,403	3,763	3,889	4,134	4,438	4,372	5,004	5,259	5,281	5,251	5,257	5,446	5,255
40-49	2,154	2,500	2,614	2,934	3,009	3,291	3,473	3,846	4,188	4,856	5,186	5,918	6,402	6,612	7,465	8,439	8,921	8,921	9,664	9,836	10,061
50-59	3,440	4,080	4,359	4,489	4,708	5,015	5,199	5,546	6,244	6,800	7,260	7,900	8,785	8,965	10,674	11,416	11,885	12,906	13,987	15,082	15,562
60-64	1,948	2,240	2,560	2,985	3,278	3,575	3,723	4,192	4,555	4,997	5,400	6,011	6,302	6,436	7,199	7,688	7,933	8,288	8,764	9,038	9,287
65-69	1,934	1,974	2,274	3,058	3,089	3,511	4,028	4,583	5,103	5,915	6,555	7,315	7,868	8,161	8,919	8,872	9,581	9,883	10,136	10,291	10,375
70-79	2,148	2,314	2,899	4,163	4,275	4,971	5,726	6,535	7,200	8,557	9,547	11,277	12,553	13,148	14,895	15,198	17,091	18,180	19,252	20,493	20,962
80+	358	376	540	847	910	1,133	1,380	1,617	1,953	2,408	2,796	3,274	3,829	4,142	4,721	5,127	6,070	6,883	7,594	8,529	9,258
Male	8,679	9,693	10,891	12,633	13,302	14,395	15,683	17,044	18,799	21,526	23,288	25,940	28,036	29,113	32,729	34,351	37,274	39,029	41,403	43,752	44,986
Female	6,990	7,988	9,047	10,542	10,901	12,208	13,185	14,672	16,294	18,403	20,015	22,667	25,033	25,564	29,275	30,913	32,877	34,545	36,645	38,288	39,199
White	9,516	11,095	13,268	15,023	15,755	17,282	18,729	20,347	22,396	25,500	27,764	31,075	33,721	34,039	38,341	39,394	42,132	45,580	47,961	51,327	52,959
Black	5,539	5,908	6,045	7,287	7,403	8,151	8,753	9,794	10,957	12,855	13,675	15,397	16,839	17,836	19,958	21,031	22,504	22,901	24,396	25,005	25,073
Other race	614	678	625	865	1,045	1,170	1,386	1,575	1,740	1,574	1,864	2,135	2,509	2,802	3,705	4,839	5,515	5,093	5,691	5,708	6,153
†Hispanic																	8,469	8,499	9,343	9,925	10,642
†Non-Hispanic																	61,682	65,075	68,705	72,115	73,543
Diabetes	2,110	3,351	4,632	5,446	6,561	7,594	8,701	9,786	11,086	13,543	15,259	17,804	19,863	19,726	23,625	26,904	30,563	32,786	35,002	36,841	38,501
Hypertension	2,438	3,786	5,107	5,574	6,231	7,129	7,740	8,789	9,942	11,792	12,712	14,408	16,078	15,416	18,112	16,756	18,245	19,395	20,511	21,749	22,214
Glomerulonephritis	1,993	2,884	3,601	3,790	3,991	4,172	4,246	4,488	4,822	5,145	5,418	5,773	6,015	5,899	6,634	7,046	7,573	7,494	7,610	7,580	7,391
Cystic kidney	610	819	985	1,013	1,031	1,084	1,132	1,164	1,150	1,169	1,274	1,351	1,433	1,398	1,573	1,664	1,651	1,743	1,843	1,898	1,857
Other urologic	254	367	377	456	454	578	571	593	646	708	746	1,000	1,055	912	1,000	1,184	1,420	1,333	1,377	1,497	1,425
Other cause	1,450	2,070	2,867	3,208	3,395	3,693	3,757	3,880	3,965	4,399	4,265	4,478	4,764	4,662	5,436	6,982	7,390	7,635	8,255	8,678	8,968
Unknown cause	1,262	1,451	1,234	1,238	1,280	1,266	1,503	1,748	1,731	1,597	1,676	2,025	2,240	1,999	2,174	2,293	2,631	2,741	3,021	3,083	3,348
Missing cause	5,552	2,953	1,135	2,450	1,260	1,087	1,218	1,268	1,751	1,576	1,953	1,768	1,621	4,665	3,450	2,435	678	447	429	714	481
All	15,669	17,681	19,938	23,175	24,203	26,603	28,868	31,716	35,093	39,929	43,303	48,607	53,069	54,677	62,004	65,264	70,151	73,574	78,048	82,040	84,185

The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90 day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.12

One-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to one year + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000
0-4	95.2	92.0	89.7	89.8	84.1	85.9	93.8	97.0	80.9	85.9	87.0	82.4	86.7	86.6	90.0	88.6	88.4	86.4	85.6	83.1	82.3
5-9	91.9	96.4	95.7	98.1	89.1	88.5	100.0	100.0	100.0	100.0	94.7	95.6	91.9	96.5	100.0	97.9	92.0	97.3	100.0	96.0	95.8
10-14	95.8	98.5	97.4	98.2	96.6	98.0	98.7	98.8	96.6	95.5	96.4	97.4	93.5	93.7	99.3	97.5	96.0	95.2	97.3	96.8	96.3
15-19	96.4	94.2	95.1	94.7	96.5	93.6	94.3	95.0	96.8	98.0	97.1	95.7	96.9	96.7	96.1	96.4	96.5	98.1	95.5	97.4	97.6
20-29	90.5	92.5	92.4	92.1	92.4	90.7	93.0	90.6	91.9	91.6	92.1	92.2	93.3	92.3	92.8	92.0	93.5	94.9	94.3	94.8	93.0
30-39	88.6	89.0	88.3	89.4	87.3	87.6	88.2	87.5	88.7	88.4	89.5	88.6	89.5	89.0	89.2	87.7	89.2	90.2	90.4	90.2	90.5
40-49	87.7	87.5	86.2	87.3	87.0	86.6	86.6	87.1	87.8	87.8	88.9	87.3	88.0	88.8	88.2	88.8	88.9	89.5	88.3	89.1	89.1
50-59	83.3	83.7	84.2	81.5	81.9	81.8	82.1	82.8	83.2	82.9	84.0	84.1	85.0	85.0	85.7	85.4	85.1	85.5	85.2	85.7	85.3
60-64	78.4	77.7	78.1	77.5	76.0	76.2	77.1	76.4	76.5	78.0	78.7	79.4	79.9	81.2	81.3	80.0	81.4	81.7	80.0	81.2	80.8
65-69	72.8	73.6	73.4	72.0	72.7	71.0	73.0	73.1	73.3	73.9	75.5	75.1	75.5	77.2	76.3	77.0	77.6	76.5	76.0	76.2	76.8
70-79	66.9	68.1	68.3	65.4	66.3	66.7	66.3	65.4	65.9	67.3	68.4	68.2	68.4	70.0	70.1	70.3	70.7	69.5	69.7	69.3	69.3
80+	57.8	53.7	62.0	55.1	56.9	57.9	58.8	55.5	55.4	57.8	59.4	59.3	58.3	60.9	60.7	60.2	60.0	59.4	57.4	58.4	58.3
Male	80.0	80.8	80.2	77.4	77.4	76.8	76.6	76.4	76.2	77.2	78.1	77.6	77.8	79.1	78.9	78.9	79.1	78.8	78.3	78.6	78.2
Female	80.8	81.1	80.9	78.6	78.6	77.8	78.5	77.1	78.1	77.9	78.6	78.0	78.4	78.8	79.0	79.0	78.9	78.2	77.3	77.3	77.2
White	79.0	79.3	78.6	75.6	75.1	74.7	74.6	73.5	74.0	74.5	75.3	74.5	74.8	75.8	76.0	76.1	76.2	75.3	74.8	75.2	75.0
Black	82.5	83.8	84.2	82.2	83.4	82.1	82.6	82.8	82.6	82.5	83.5	83.1	83.4	83.5	83.3	82.9	83.1	83.6	82.3	82.3	81.8
Other race	80.8	80.6	84.2	81.3	81.2	80.7	82.5	79.1	81.9	84.8	85.5	86.5	85.2	87.2	85.3	84.1	83.1	84.4	83.4	83.6	84.8
†Hispanic																	83.4	82.9	83.1	82.9	84.1
†Non-Hispanic																	78.4	77.9	77.1	77.3	76.8
Diabetes	73.5	73.1	72.8	72.7	72.9	72.4	73.7	73.7	74.8	75.8	76.1	76.5	76.8	78.8	78.3	78.2	78.5	77.8	77.1	77.8	77.8
Hypertension	82.3	81.4	80.0	77.9	77.4	77.9	76.9	75.1	75.0	75.8	77.0	76.0	76.3	77.0	76.9	78.2	78.0	77.2	76.5	76.5	76.4
Glomerulonephritis	90.4	88.8	88.0	86.9	86.8	86.6	85.1	85.2	85.4	85.2	85.9	84.6	86.4	87.5	86.0	87.0	87.8	87.5	87.8	87.2	87.4
Other cause	79.3	81.3	82.5	77.6	78.3	76.7	78.4	77.7	78.1	78.2	79.6	79.0	78.6	77.6	79.5	77.3	76.8	77.4	76.4	76.2	75.2
All	80.4	80.9	80.5	78.0	77.9	77.3	77.5	76.7	77.1	77.5	78.3	77.8	78.1	78.9	78.9	78.9	79.0	78.5	77.8	78.0	77.8
ADJUSTED																					
0-19	92.5	91.3	91.2	91.1	89.1	87.2	92.0	93.6	90.3	92.8	91.6	88.9	89.8	90.3	93.7	92.0	90.7	91.9	90.6	91.4	90.1
20-44	87.2	88.5	88.2	88.5	87.7	87.4	88.1	87.6	88.6	88.1	89.4	88.4	89.0	88.6	88.9	88.1	89.3	90.1	89.7	90.0	90.0
45-64	80.1	80.3	81.1	79.9	79.7	79.8	80.5	80.6	81.0	82.0	82.9	83.1	84.0	84.7	84.9	84.5	85.0	85.6	84.7	85.5	85.2
65-74	69.5	70.4	72.0	69.2	70.1	69.1	70.4	70.5	71.0	71.9	73.5	73.2	73.7	75.3	74.7	75.5	76.0	75.2	75.0	75.2	75.5
75+	59.9	61.9	61.6	58.6	60.8	62.0	62.1	59.2	60.0	62.3	63.3	63.4	62.8	64.1	65.0	64.5	64.8	63.9	63.2	63.5	63.4
Male	74.2	75.3	75.5	73.5	73.7	73.6	74.1	74.0	74.1	75.6	76.8	76.7	77.1	78.5	78.5	78.3	79.2	79.3	78.8	79.5	79.2
Female	75.5	76.1	77.0	75.5	75.9	75.6	76.9	75.9	77.1	77.5	78.5	78.2	78.8	79.2	79.5	79.5	79.8	79.5	78.8	78.9	79.1
White	72.7	73.4	73.7	71.7	71.6	71.9	72.6	71.9	72.8	74.1	75.1	74.9	75.5	76.6	77.1	77.3	77.9	77.4	77.1	77.7	77.7
Black	78.7	79.4	80.1	78.8	80.1	78.8	79.8	80.2	79.9	80.0	81.4	81.2	81.6	82.0	81.5	81.0	81.5	82.1	80.9	80.9	80.6
Other race	74.6	75.1	79.0	76.9	76.5	77.5	80.1	76.8	79.8	83.3	84.3	85.4	84.5	86.5	84.2	83.6	82.8	84.2	83.2	83.8	84.8
Diabetes	68.8	68.6	68.9	69.2	69.8	69.4	71.3	71.4	73.0	74.3	74.9	75.5	76.0	78.2	77.9	77.6	78.1	77.8	77.2	78.1	78.3
Hypertension	79.8	79.7	79.1	77.7	77.4	78.6	78.3	77.1	77.2	78.2	79.7	79.0	79.1	79.9	80.0	80.9	80.9	80.5	80.0	80.2	80.2
Glomerulonephritis	86.0	84.7	84.0	83.0	83.3	83.8	82.2	82.5	82.5	83.0	83.8	82.7	84.4	85.5	84.4	85.0	86.2	85.8	86.0	85.7	85.7
Other cause	76.6	77.8	79.6	76.4	76.7	75.1	77.2	76.6	76.7	77.0	78.4	77.9	77.9	77.8	78.2	76.2	76.0	76.9	75.9	75.8	75.0
All	74.8	75.6	76.2	74.4	74.7	74.6	75.4	74.9	75.5	76.5	77.7	77.5	77.9	78.8	79.0	78.9	79.4	79.4	78.8	79.2	79.2

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age or gender, or of age >110 are excluded.

Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories; no unknown or foreign states.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.13

Two-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to two years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999
0-4	77.6	89.1	85.9	79.1	81.8	78.6	85.9	86.0	71.6	80.6	79.4	80.8	86.7	85.1	83.7	81.9	83.6	81.4	79.6	82.0
5-9	87.8	96.4	90.9	89.2	83.8	88.5	81.7	100.0	100.0	95.8	85.7	95.6	91.9	88.0	96.1	95.5	90.2	97.3	94.5	94.4
10-14	94.3	94.5	93.0	96.3	90.3	96.1	94.5	98.8	93.8	95.5	89.0	96.1	90.8	90.9	97.0	93.6	92.5	91.2	93.8	96.8
15-19	94.5	89.9	91.2	89.9	92.8	91.6	88.2	93.6	94.6	95.7	94.2	92.6	94.7	92.7	94.2	93.6	90.7	93.1	92.4	92.8
20-29	82.1	84.4	84.5	82.7	84.2	79.9	84.1	80.9	84.8	84.9	84.4	84.7	86.5	86.6	87.1	85.9	87.8	89.0	89.9	89.8
30-39	78.3	79.4	77.6	79.7	75.5	74.9	75.8	76.4	79.0	78.3	79.0	78.2	79.3	80.4	79.8	79.4	80.5	82.3	81.9	82.8
40-49	76.0	75.6	75.3	74.8	74.5	74.8	73.7	74.0	75.7	75.5	78.5	74.9	77.1	77.1	77.6	78.6	78.4	79.5	78.9	79.2
50-59	70.3	70.2	70.5	67.7	66.6	66.5	66.6	66.7	67.8	69.1	69.4	69.8	70.8	71.6	72.9	72.0	72.4	72.8	71.8	73.1
60-64	63.8	61.4	61.4	61.8	59.0	58.2	60.3	59.1	59.8	61.1	61.6	63.0	63.4	65.1	65.7	64.1	66.1	66.3	64.7	66.6
65-69	54.7	56.1	55.1	52.2	55.2	52.9	53.8	55.2	55.9	56.0	56.5	56.8	58.0	59.8	58.8	59.5	60.5	58.8	59.0	59.3
70-79	46.6	48.7	48.9	44.2	46.5	46.9	46.4	45.5	46.4	47.7	47.9	48.2	49.1	50.1	50.4	50.7	51.5	49.6	50.7	50.7
80+	30.4	33.7	37.4	30.3	36.8	35.6	35.1	33.3	33.1	37.4	36.7	36.3	36.6	37.5	38.4	38.3	38.1	37.1	37.1	37.4
Male	64.7	65.9	64.6	60.7	61.0	58.7	59.4	58.8	59.8	60.8	61.1	60.8	61.5	62.9	63.1	63.6	63.6	63.1	63.1	63.6
Female	66.9	67.0	66.2	62.5	62.7	62.3	61.5	60.8	61.9	62.0	62.2	61.4	62.5	62.5	63.2	63.0	63.4	62.2	61.9	62.1
White	63.3	64.0	62.3	58.1	57.6	56.5	55.8	55.4	55.8	56.5	56.6	56.0	56.8	57.3	58.1	58.3	58.6	57.3	57.7	58.5
Black	69.3	70.7	71.2	67.7	69.5	67.9	68.6	67.6	69.6	69.3	69.8	69.1	70.1	70.7	70.8	70.5	70.7	70.9	69.8	69.6
Other race	68.0	65.4	70.4	64.8	66.4	62.9	66.2	64.0	67.2	71.6	71.6	75.0	73.4	74.7	72.5	70.8	70.4	71.7	70.9	71.9
†Hispanic																	69.6	69.1	69.6	70.5
†Non-Hispanic																	62.7	61.8	61.6	61.9
Diabetes	54.6	53.1	52.2	54.0	51.4	51.4	52.5	53.1	55.0	56.7	56.4	57.2	58.2	60.4	59.9	60.2	60.9	60.1	59.9	61.0
Hypertension	68.1	66.8	65.4	61.8	62.8	61.4	60.3	58.3	59.3	60.1	60.1	59.4	60.5	61.0	61.5	63.0	62.9	61.4	61.4	61.4
Glomerulonephritis	80.0	77.3	76.7	74.5	75.3	72.7	71.6	71.8	73.5	72.2	73.5	71.7	74.4	76.0	74.6	76.1	76.6	76.3	77.7	76.7
Other cause	64.7	68.2	69.1	60.9	63.3	62.3	63.8	63.3	63.6	64.6	65.8	65.1	64.8	62.7	65.9	63.7	63.6	63.9	63.4	63.2
All	65.7	66.4	65.4	61.5	61.8	60.4	60.4	59.8	60.8	61.4	61.6	61.1	62.0	62.7	63.2	63.3	63.5	62.7	62.6	62.9
ADJUSTED																				
0-19	88.2	85.2	84.8	82.6	82.4	83.1	80.2	90.2	85.2	88.9	83.5	85.3	86.9	84.5	89.0	86.1	83.0	84.7	84.5	86.9
20-44	75.0	77.7	77.1	77.2	75.5	74.4	75.7	75.6	78.0	77.8	79.1	77.4	78.8	78.8	79.3	79.0	80.1	81.8	81.3	82.0
45-64	65.6	64.8	65.9	64.7	63.5	63.4	64.4	64.0	65.3	67.1	68.0	68.4	69.5	70.7	71.6	71.1	72.1	72.7	71.8	73.1
65-74	49.5	52.1	53.2	48.5	51.6	50.3	51.1	51.9	53.0	53.6	54.0	54.6	55.9	56.7	56.6	57.9	58.5	57.1	57.8	58.2
75+	37.5	41.0	39.5	35.4	40.1	40.7	40.0	37.9	38.5	41.9	41.7	41.8	42.0	43.0	43.9	43.3	44.3	42.8	43.5	43.9
Male	56.7	58.3	58.2	55.6	56.4	55.2	56.6	56.0	57.4	59.2	59.8	60.1	60.9	62.5	62.9	63.2	64.0	64.1	64.2	65.2
Female	59.5	60.0	60.9	58.5	59.4	59.8	59.7	59.8	61.0	61.9	62.5	62.4	63.6	63.6	64.5	64.3	65.2	64.5	64.4	64.8
White	54.8	56.1	56.0	53.4	53.8	53.7	54.0	54.2	55.1	56.9	57.3	57.4	58.6	59.3	60.5	60.8	61.8	61.1	61.7	62.6
Black	63.6	64.0	64.9	62.7	64.5	63.2	64.7	63.9	65.7	65.8	66.8	66.4	67.4	68.5	68.2	67.8	68.5	68.8	67.7	67.6
Other race	59.6	58.0	62.9	58.6	60.2	59.2	62.8	61.3	64.6	69.7	70.1	73.7	72.5	74.1	71.2	70.1	70.2	71.8	70.9	72.5
Diabetes	48.9	47.8	47.7	49.8	47.9	48.3	49.8	50.6	53.0	55.1	55.1	56.3	57.5	59.7	59.7	59.7	60.7	60.3	60.2	61.7
Hypertension	64.8	64.8	64.6	62.0	63.4	63.2	63.0	61.7	62.7	64.0	64.5	64.1	64.9	65.7	66.3	67.1	67.5	66.5	66.7	66.9
Glomerulonephritis	72.6	71.0	70.7	69.0	70.5	68.9	68.1	68.4	69.8	69.4	70.7	69.3	71.6	73.0	72.5	73.1	74.2	73.7	74.9	74.5
Other cause	61.2	63.5	65.1	59.8	61.7	60.8	62.6	62.2	62.3	63.5	64.6	63.9	64.3	63.4	64.4	62.5	62.8	63.4	63.0	63.0
All	58.0	59.1	59.5	57.0	57.8	57.4	58.1	57.8	59.1	60.5	61.1	61.2	62.2	63.0	63.6	63.7	64.6	64.3	64.3	65.0

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis.

Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule.

The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.14

Five-year Survival Probabilities: Incident Dialysis Patients

censored at transplant, from day 91 to five years + 90 days, by age, gender, race, ethnicity, & primary diagnosis

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996
0-4	77.6	75.2	85.9	79.1	65.8	64.8	85.9	80.9	68.2	76.4	71.4	70.6	65.2	71.4	74.1	74.9	70.5
5-9	87.8	85.0	70.1	79.2	83.8	57.5	72.6	81.8	91.7	86.3	75.5	95.6	78.2	75.0	88.0	82.3	87.5
10-14	79.7	76.7	84.7	93.7	83.0	96.1	78.1	82.8	77.6	85.1	81.1	81.2	78.2	75.6	83.7	86.1	85.3
15-19	87.6	80.7	78.7	84.8	83.1	70.6	74.7	82.9	77.0	80.2	85.4	83.3	85.3	80.2	82.7	85.0	83.3
20-29	73.2	67.8	68.2	64.0	62.2	59.3	65.5	61.8	67.8	64.6	67.5	68.3	69.7	70.9	72.7	73.3	74.7
30-39	59.4	58.6	53.7	54.9	53.3	51.2	51.2	49.1	55.4	55.7	55.5	55.0	56.4	59.0	58.2	59.3	60.4
40-49	51.3	50.6	49.8	46.4	48.2	47.0	47.1	47.1	48.9	46.6	48.5	47.9	48.9	49.9	50.5	53.0	52.1
50-59	40.0	40.4	39.5	37.0	35.3	34.3	35.3	36.4	35.8	36.0	35.7	38.1	37.4	39.8	40.2	40.5	40.5
60-64	31.6	31.0	29.2	29.2	26.4	26.3	27.4	26.1	28.0	28.1	29.0	29.2	29.5	30.4	31.6	30.3	31.9
65-69	23.0	24.7	24.0	20.7	22.2	22.2	22.0	22.7	22.6	22.7	21.8	23.8	24.0	24.9	24.4	25.2	
70-79	16.0	16.0	17.2	13.8	15.4	15.5	14.8	15.3	15.5	16.1	15.7	16.1	16.0	16.7	16.9	17.4	18.0
80+	7.0	5.9	6.1	6.5	7.5	8.3	7.4	7.8	6.7	8.9	8.7	7.9	7.6	8.1	8.3	9.0	8.9
Male	36.2	35.1	33.8	29.4	29.0	27.4	28.0	28.0	28.8	29.3	29.0	29.2	29.0	30.5	31.2	32.7	32.4
Female	38.3	39.1	36.2	32.5	32.1	31.2	30.4	29.8	30.7	29.7	29.9	29.4	30.0	30.0	31.0	31.1	31.4
White	34.9	33.0	31.3	26.8	26.1	24.8	24.0	23.7	23.6	23.6	23.2	23.1	23.3	23.9	24.6	25.0	25.4
Black	40.8	43.8	41.8	37.5	38.5	37.3	38.1	37.5	39.9	38.6	39.5	39.2	39.3	39.7	40.7	42.2	41.3
Other race	34.3	34.8	40.2	38.1	33.8	31.1	35.3	36.1	38.3	42.2	40.3	41.8	40.5	41.7	41.3	40.2	40.3
†Hispanic																	39.1
†Non-Hispanic																	30.9
Diabetes	23.9	21.8	19.5	20.2	18.5	17.9	20.0	19.8	21.4	21.3	21.4	22.3	22.9	24.5	24.8	25.1	25.8
Hypertension	40.2	36.4	34.8	31.9	31.2	30.8	29.2	27.9	29.3	29.5	29.5	28.3	29.1	29.6	29.9	32.6	32.5
Glomerulonephritis	54.3	50.6	49.1	45.1	44.3	40.3	40.5	41.2	43.4	42.2	42.9	43.0	44.1	46.7	46.1	48.9	49.1
Other cause	36.2	39.8	39.8	31.8	34.4	34.3	34.4	35.3	34.7	36.1	36.3	37.1	35.8	33.8	38.1	37.4	37.4
All	37.1	37.0	34.9	30.9	30.5	29.3	29.2	28.9	29.7	29.5	29.4	29.3	29.5	30.3	31.1	31.9	31.9
ADJUSTED																	
0-19	76.3	67.6	68.4	76.0	69.2	58.1	63.5	72.9	64.6	70.6	71.0	71.1	70.5	66.1	72.2	73.8	71.8
20-44	55.2	54.9	52.6	51.0	51.1	48.5	51.5	49.7	53.5	53.2	54.6	53.7	54.7	56.0	56.6	57.5	58.2
45-64	33.9	33.9	34.2	32.7	31.2	31.0	32.4	32.4	33.5	34.0	34.6	36.5	36.4	38.2	39.1	39.7	40.6
65-74	18.3	20.0	20.8	17.3	19.1	19.4	18.9	19.9	20.4	20.8	21.0	20.6	22.1	22.0	23.1	23.2	24.2
75+	10.2	10.2	10.6	8.6	10.4	10.9	10.8	10.5	10.0	12.0	11.0	11.6	10.6	11.4	11.6	12.5	12.9
Male	28.6	28.2	28.5	25.9	26.2	26.1	27.1	27.1	27.9	29.4	29.2	30.1	30.0	31.6	32.2	33.2	34.0
Female	30.6	32.0	31.6	29.7	30.4	30.3	30.5	30.6	31.4	31.4	31.9	32.1	33.0	33.0	34.0	34.1	35.0
White	27.1	26.3	26.5	24.2	24.6	24.7	24.8	24.9	25.3	26.6	26.3	26.8	27.5	28.3	29.4	29.7	31.0
Black	34.0	36.0	34.6	32.3	33.5	32.8	34.4	34.2	35.9	35.1	36.5	36.7	36.7	37.7	38.1	39.2	38.9
Other race	27.3	29.0	32.9	32.8	29.3	29.8	33.4	34.9	36.6	41.7	39.7	42.2	41.1	42.3	41.0	40.6	41.3
Diabetes	20.3	18.7	17.6	18.3	17.4	17.4	19.3	19.4	20.9	21.4	21.5	22.7	23.4	25.1	25.7	25.8	26.6
Hypertension	37.4	35.3	35.8	33.8	33.6	34.4	33.9	33.6	34.6	35.3	35.8	35.2	35.6	36.2	36.6	38.3	38.7
Glomerulonephritis	44.9	43.5	42.9	40.2	40.6	37.9	38.7	39.0	40.9	40.9	40.7	42.0	42.2	44.0	44.4	45.4	46.3
Other cause	33.3	35.4	36.4	31.7	34.3	34.1	34.9	35.5	34.6	36.4	36.1	36.9	36.5	35.7	37.3	36.7	37.2
All	29.5	30.0	30.0	27.7	28.2	28.0	28.7	28.8	29.5	30.3	30.4	31.0	31.4	32.2	33.0	33.6	34.4

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation.

Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

Table I.15

Ten-year Survival Probabilities: Incident Dialysis Patients*censored at transplant, from day 91 to ten years + 90 days, by age, gender, race, & primary diagnosis*

UNADJUSTED	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991
0-4	77.6	75.2	64.5	63.3	56.4	25.9	85.9	80.9	51.1	76.4	56.2	64.7
5-9	87.8	67.6	52.6	79.2	83.8	38.3	72.6	81.8	91.7	73.9	56.6	57.3
10-14	58.9	54.8	64.3	80.1	66.6	87.4	68.4	76.9	58.8	61.1	63.8	74.4
15-19	77.4	61.5	66.7	71.0	60.2	54.3	55.3	58.5	63.3	66.6	63.5	69.3
20-29	53.3	46.5	47.8	44.1	43.2	42.8	42.6	41.3	45.9	42.3	46.5	45.1
30-39	38.5	34.7	31.3	32.7	31.8	30.2	29.2	28.0	30.1	31.6	32.5	31.8
40-49	24.3	23.7	22.6	22.1	23.6	21.2	20.8	21.3	22.8	19.4	20.9	20.6
50-59	12.9	14.1	14.0	11.8	11.2	12.2	10.8	11.3	10.8	11.1	11.0	11.9
60-64	7.9	8.0	6.1	7.6	7.0	7.4	7.0	6.0	6.9	6.2	6.8	7.1
65-69	4.6	5.0	3.9	4.7	5.1	5.7	4.6	4.1	4.3	4.2	4.6	4.1
70-79	2.5	2.2	2.9	2.3	2.8	2.7	2.2	2.4	2.2	2.1	2.0	1.9
80+	1.4	0.5	1.5	0.2	1.2	0.9	0.5	0.9	0.4	0.6	0.4	0.8
Male	13.3	12.3	11.4	10.2	10.3	9.8	9.5	9.2	9.2	8.9	9.4	9.0
Female	15.4	15.3	13.0	11.7	11.3	10.9	9.4	9.1	9.9	9.0	8.9	9.0
White	12.7	11.2	10.3	8.8	8.7	7.9	6.9	6.8	6.3	6.0	6.3	6.1
Black	16.7	17.7	15.5	14.3	14.3	14.7	13.5	12.8	14.6	13.7	13.8	13.6
Other race	12.7	14.2	15.4	15.5	14.1	12.2	13.8	13.0	14.6	14.8	14.6	14.0
Diabetes	6.2	5.5	4.6	4.5	4.2	4.3	4.1	4.3	4.5	4.0	4.1	4.0
Hypertension	13.6	12.3	10.8	11.0	10.7	10.2	9.3	7.9	8.9	8.9	8.4	8.3
Glomerulonephritis	27.2	22.4	20.2	18.6	19.4	17.8	17.2	17.0	17.8	16.2	17.9	16.7
Other cause	14.2	15.8	15.6	12.4	13.1	13.6	12.6	13.1	13.4	13.8	15.3	16.3
All	14.3	13.8	12.2	10.9	10.7	10.3	9.4	9.1	9.5	9.0	9.2	9.0
ADJUSTED												
0-19	58.7	45.2	46.9	56.9	44.5	38.1	42.2	49.1	46.8	52.1	46.3	51.8
20-44	32.4	29.7	28.0	28.2	28.6	27.4	27.6	26.7	28.2	28.3	29.6	29.0
45-64	9.6	10.2	10.4	9.8	9.6	10.0	9.8	9.8	10.2	9.9	10.5	11.3
65-74	3.1	3.4	3.4	3.4	4.0	4.5	3.6	3.5	3.5	3.6	3.8	3.5
75+	1.2	1.3	1.8	0.8	1.7	1.4	1.2	1.5	1.2	1.1	0.8	1.2
Male	10.2	9.8	10.1	9.5	10.2	10.7	10.4	10.2	9.9	10.2	10.6	10.7
Female	11.8	12.3	12.0	11.5	12.0	12.1	11.0	11.4	11.9	11.6	11.7	12.1
White	9.7	9.3	9.4	8.9	9.6	9.7	9.2	9.2	8.9	9.1	9.5	9.7
Black	12.6	13.1	12.2	11.8	12.2	12.8	12.1	12.0	13.1	12.3	12.8	13.0
Other race	9.9	11.8	14.1	13.6	13.0	13.2	14.2	14.4	15.0	16.9	15.7	16.5
Diabetes	5.4	5.0	4.7	4.6	4.6	5.0	4.5	4.9	5.0	4.5	4.8	4.8
Hypertension	13.8	13.5	13.4	13.8	13.8	14.2	13.6	13.1	13.2	13.5	13.2	13.3
Glomerulonephritis	20.4	18.6	17.9	16.8	18.6	18.1	17.6	17.0	17.6	16.8	17.4	17.3
Other cause	13.7	14.5	15.0	13.5	14.7	15.1	14.3	14.6	14.5	15.3	16.1	17.2
All	10.9	10.9	11.0	10.4	11.0	11.3	10.7	10.7	10.8	10.8	11.1	11.3

Reference cohort is 1996 incident ESRD patients. Overall adjusted survival probabilities are adjusted for age, gender, race, & primary diagnosis. Adjusted survival probabilities for one of the four variables is adjusted for the remaining three. The incident cohorts are determined at the time of ESRD initiation with the 60-day stable modality rule & the 90-day rule. The age of the incident patient is determined as of the date of ESRD initiation. Patients of unknown age or gender, or of age >110 are excluded. Includes residents of the 50 states, the District of Columbia, Puerto Rico, & the Territories.

